[ET Net News Agency, 19 September 2019] 3SBio Inc. (01530) said the clinical trial
application of the group's oral disintegration tablet of nalfurafine hydrochloride (the
TRK820), a drug to treat the pruritus of hemodialysis patients, has been approved by the
National Medical Products Administration to conduct clinical trials.
The soft capsule dosage-form of the TRK-820 has been sold in Japan since 2009 to treat
hemodialysis-related uremic pruritus (which is used only when sufficient efficacy of the
existing therapies or treatments is not achieved). (RC)